Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
R De Caterina, P Kelly, P Monteiro… - Journal of …, 2019 - journals.lww.com
Aim Edoxaban, a nonvitamin K antagonist oral anticoagulant, is an oral factor Xa inhibitor
approved for the prevention of stroke and systemic embolism in adult patients with atrial …
approved for the prevention of stroke and systemic embolism in adult patients with atrial …
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
R de Caterina, P Kelly, P Monteiro, JC Deharo… - Journal of …, 2019 - hal.science
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with
Atrial Fibrillation in Europe (ETNA-AF-Europe) study - Archive ouverte HAL Accéder …
Atrial Fibrillation in Europe (ETNA-AF-Europe) study - Archive ouverte HAL Accéder …
[引用][C] Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
R De Caterina, P Kelly, P Monteiro, JC Deharo… - JOURNAL OF …, 2019 - arpi.unipi.it
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with
Atrial Fibrillation in Europe (ETNA-AF-Europe) study IRIS IRIS Home Sfoglia Macrotipologie …
Atrial Fibrillation in Europe (ETNA-AF-Europe) study IRIS IRIS Home Sfoglia Macrotipologie …
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
R De Caterina, P Kelly, P Monteiro… - Journal of …, 2019 - zora.uzh.ch
AIM Edoxaban, a nonvitamin K antagonist oral anticoagulant, is an oral factor Xa inhibitor
approved for the prevention of stroke and systemic embolism in adult patients with atrial …
approved for the prevention of stroke and systemic embolism in adult patients with atrial …
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
R De Caterina, P Kelly, P Monteiro, JC Deharo… - Journal of …, 2019 - sonar.ch
METHODS The ETNA-AF-Europe study (Clinicaltrials. gov: NCT02944019) is a multicenter,
prospective, observational study that enrolled 13 980 patients with atrial fibrillation treated …
prospective, observational study that enrolled 13 980 patients with atrial fibrillation treated …
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
R De Caterina, P Kelly, P Monteiro… - Journal of …, 2019 - folia.unifr.ch
METHODS The ETNA-AF-Europe study (Clinicaltrials. gov: NCT02944019) is a multicenter,
prospective, observational study that enrolled 13 980 patients with atrial fibrillation treated …
prospective, observational study that enrolled 13 980 patients with atrial fibrillation treated …
[PDF][PDF] Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
R De Caterina, P Kelly, P Monteiro, JC Deharo… - J Cardiovasc …, 2019 - core.ac.uk
Aim Edoxaban, a nonvitamin K antagonist oral anticoagulant, is an oral factor Xa inhibitor
approved for the prevention of stroke and systemic embolism in adult patients with atrial …
approved for the prevention of stroke and systemic embolism in adult patients with atrial …
[引用][C] Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
R de Caterina, P Kelly, P Monteiro, JC Deharo… - 2019 - ideas.repec.org
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial
Fibrillation in Europe (ETNA-AF-Europe) study IDEAS home Advanced search Economic literature …
Fibrillation in Europe (ETNA-AF-Europe) study IDEAS home Advanced search Economic literature …
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
R de Caterina, P Kelly, P Monteiro, JC Deharo… - 2019 - econpapers.repec.org
EconPapers: Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for
patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study EconPapers Economics at …
patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study EconPapers Economics at …
[PDF][PDF] Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
R De Caterina, P Kelly, P Monteiro… - J Cardiovasc …, 2019 - research.birmingham.ac.uk
Aim Edoxaban, a nonvitamin K antagonist oral anticoagulant, is an oral factor Xa inhibitor
approved for the prevention of stroke and systemic embolism in adult patients with atrial …
approved for the prevention of stroke and systemic embolism in adult patients with atrial …